1.Le Lay J, Kaestner KH: The Fox genes in the liver: from organogenesis to functional integration. Physiological reviews 2010, 90(1):1–22.
2.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394–424.
3.El-Serag HB: Hepatocellular carcinoma. The New England journal of medicine 2011, 365(12):1118–1127.
4.Kaplan MM, Gershwin ME: Primary biliary cirrhosis. The New England journal of medicine 2005, 353(12):1261–1273.
5.Lazo M, Clark JM: The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in liver disease 2008, 28(4):339–350.
6.Angulo P: Nonalcoholic fatty liver disease. The New England journal of medicine 2002, 346(16):1221–1231.
7.Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, Bodenmiller B, Campbell P, Carninci P, Clatworthy M et al: The Human Cell Atlas. eLife 2017, 6.
8.Han X, Wang R, Zhou Y, Fei L, Sun H, Lai S, Saadatpour A, Zhou Z, Chen H, Ye F et al: Mapping the Mouse Cell Atlas by Microwell-Seq. Cell 2018, 173(5):1307.
9.MacParland SA, Liu JC, Ma XZ, Innes BT, Adeyi O, Keller G, Bader GD, McGilvray ID, Greig P, Sapisochin G et al: Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nature communications 2018, 9(1):4383.
10.Gallagher MD, Chen-Plotkin AS: The Post-GWAS Era: From Association to Function. American journal of human genetics 2018, 102(5):717–730.
11.Wijmenga C, Zhernakova A: The importance of cohort studies in the post-GWAS era. Nature genetics 2018, 50(3):322–328.
12.Huang Q: Genetic study of complex diseases in the post-GWAS era. Journal of genetics and genomics = Yi chuan xue bao 2015, 42(3):87–98.
13.Do C, Shearer A, Suzuki M, Terry MB, Gelernter J, Greally JM, Tycko B: Genetic-epigenetic interactions in cis: a major focus in the post-GWAS era. Genome biology 2017, 18(1):120.
14.Hook PW, McClymont SA, Cannon GH, Law WD, Morton AJ, Goff LA, McCallion AS: Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs Candidate Gene Selection for Sporadic Parkinson Disease. American journal of human genetics 2018, 102(3):427–446.
15.MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, Hastings E, Junkins H, McMahon A, Milano A, Morales J et al: The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic acids research 2017, 45(D1):D896-d901.
16.Durinck S, Spellman PT, Birney E, Huber W: Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nature protocols 2009, 4(8):1184–1191.
17.Satija R, Farrell JA, Gennert D, Schier AF, Regev A: Spatial reconstruction of single-cell gene expression data. Nature biotechnology 2015, 33(5):495–502.
18.Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ: Primary biliary cirrhosis. Hepatology (Baltimore, Md) 2009, 50(1):291–308.
19.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet Gastroenterology & hepatology 2018, 3(6):383–403.
20.Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic reviews 2006, 28:112–125.
21.Chisari FV, Ferrari C: Hepatitis B virus immunopathogenesis. Annual review of immunology 1995, 13:29–60.
22.Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nature reviews Immunology 2005, 5(3):215–229.
23.Rozga J, Piatek T, Malkowski P: Human albumin: old, new, and emerging applications. Annals of transplantation 2013, 18:205–217.
24.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md) 2016, 64(1):73–84.
25.Sporea I, Popescu A, Dumitrascu D, Brisc C, Nedelcu L, Trifan A, Gheorghe L, Fierbinteanu Braticevici C: Nonalcoholic Fatty Liver Disease: Status Quo. Journal of gastrointestinal and liver diseases: JGLD 2018, 27(4):439–448.
26.Pares A: Old and novel therapies for primary biliary cirrhosis. Seminars in liver disease 2014, 34(3):341–351.
27.Czul F, Levy C: Novel Therapies on Primary Biliary Cirrhosis. Clinics in liver disease 2016, 20(1):113–130.